Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305272 | 0.83 | XIAP (0.55) | KDM4EXIAPBIRC2TDP1KMT2A | |
| SCHEMBL3146288 | 0.80 | GAA (0.54) | KDM4EL3MBTL1TDP1POLBALDH1A1 | |
| SCHEMBL24742274 | 0.78 | CYP3A4 (0.51) | CA1CA2KDM4EL3MBTL1TDP1 | |
| SCHEMBL16765682 | 0.77 | NQO2 (0.50) | CA1CA2KDM4EBCHENQO2 | |
| SCHEMBL15584781 | 0.77 | CA1 (0.62) | CA1CA2KDM4EL3MBTL1TDP1 | |
| SCHEMBL8290128 | 0.76 | HDAC3 (0.55) | CA1CA2 | |
| SCHEMBL28734996 | 0.76 | XIAP (0.56) | KDM4EXIAPBIRC2TDP1ADORA3 | |
| SCHEMBL8692897 | 0.76 | CA1 (0.66) | CA1CA2KDM4EL3MBTL1TDP1 | |
| SCHEMBL8692644 | 0.76 | POLB (0.55) | CA1CA2KDM4EL3MBTL1TDP1 | |
| SCHEMBL431114 | 0.75 | XIAP (0.55) | KDM4EXIAPBIRC2TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| WO-2012011114-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2012-01-26 | — | — | WO | disclosed |
| US-20100284959-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENE ARREST LTD. (IL) | 2010-11-11 | — | — | US | disclosed |
| US-20100284959-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENE ARREST LTD. (IL) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284959-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | POLRMT, POLM, SNRPE | CA1 4047/4885CA2 3565/4885KDM4E 3161/4885 |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | POLM, POLRMT, DDB1 | CA1 4239/4885CA2 3832/4885KDM4E 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.